Background: The diagnosis and treatment of lung cancer is currently governed by the selection of patients based on oncogenic alterations that allow specific therapies to be offered. The gene (ALK) is present in 3 to 7% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK inhibitors with better response rates and PFS than with chemotherapy. Method: We performed a descriptive review of the response profile in patients with NSCLC with positive ALK mutation and who received treatment with alectinib. Tomography patterns were described, as well as the response achieved with the treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.